Product Description
TGRX-326 is being developed by Shenzhen Tajirui Biological Medicine for the treatment of non-small cell lung cancer. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05441956?term=TGRX-326&draw=2&rank=1)
Mechanisms of Action: ALK Inhibitor,ROS Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shenzhen Tagirui Biopharmaceutical Co., Ltd.
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 6
Highest Development Phases
Phase 2: Non-Small-Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TGRX-326-1001 | P1 |
Active, not recruiting |
Non-Small-Cell Lung Cancer |
2025-08-31 |
|
| TGRX-326-1004 | P1 |
Completed |
Non-Small-Cell Lung Cancer |
2024-07-08 |
|
| TGRX-326-1003 | P1 |
Completed |
Non-Small-Cell Lung Cancer |
2024-05-06 |
|
| TGRX-326-2001-NSCLC-CN | P2 |
Recruiting |
Non-Small-Cell Lung Cancer |
2024-02-28 |